Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Medicinal and biological chemistry (MBC) library: an efficient source on new hits, The medicinal and biological chemistry (MBC) library: an efficient source on new hits

  • Sebastián-Pérez, Víctor
  • Roca, Carlos
  • Awale, Mahendra
  • Reymond, Jean-Louis
  • Martínez Gil, Ana
  • Gil, Carmen
  • Campillo, Nuria E.
22 p.-6 fig.-3 tab., Identification of new hits is one of the biggest challenges in drug discovery. Creating a library of well-characterized drug-like compounds is a key step in this process. Our group has developed an in-house chemical library called Medicinal and Biological Chemistry (MBC) library. This collection has been successfully used to start several medicinal chemistry programs and developed in an accumulation of more than thirty years of experience in drug design and discovery of new drugs for unmet diseases. It contains over 1,000 compounds, mainly heterocyclic scaffolds. In this work, an analysis of drug-like properties and comparative study with well-known libraries by using different computer software is here presented., Financial support from MINECO (grant no. CTQ2015-66313 and SAF2015-65740) and the EC 7th Framework Programme (FP7-HEALTH-2013-INNOVATION-1, PDE4NPD no. 602666). We also thanks to MECD (Grant of V.S, FPU15/01465)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cyclic nucleotide specific phosphodiesterases as potential drug targets for anti-Leishmania therapy, PDEs: therapeutic targets for leishmaniasis

  • Sebastián-Pérez, Víctor
  • Hendrickx, Sarah
  • Munday, Jane C.
  • Kalejaiye, Titilola
  • Martínez Gil, Ana
  • Campillo, Nuria E.
  • Koning, Harry de
  • Caljon, Guy
  • Maes, Louis
  • Gil, Carmen
The available treatments for leishmaniasis are less than optimal due to inadequate efficacy, toxic side-effects and the emergence of resistant strains, clearly endorsing the urgent need for discovery and development of novel drug candidates. Ideally, these should act via an alternative mechanism-of-action to avoid cross-resistance with the current drugs. As cyclic nucleotide specific phosphodiesterases (PDEs) of L. major have been postulated as putative drug targets, a series of potential inhibitors of Leishmania PDEs was explored. Several displayed potent and selective in vitro activity against L. infantum intracellular amastigotes. One imidazole derivative, compound 35, was shown to reduce the parasite loads in vivo and dose-dependently increase the cellular cAMP level at just 2* and 5* the IC50, indicating a correlation between antileishmanial activity and increased cellular cAMP. Docking studies and molecular dynamics simulations pointed to imidazole 35 exerting its activity through PDE inhibition. This study establishes for the first time that inhibition of cAMP PDEs can potentially be exploited for new antileishmanial chemotherapy., Funding from the EC 7th Framework Programme (FP7-HEALTH-2013 INNOVATION-1, PDE4NPD no. 602666), MINECO (Grant SAF2015-65740-R), RICET (RD16/0027/0010), FEDER funds and MECD (Grant FPU15/1465 to V. S.-P.) is acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Screening of a PDE-focused library identifies imidazoles with in vitro and in vivo antischistosomal activity

  • Botros, Sanaa S.
  • William, Samia
  • Sabra, Abdel-Nasser A.
  • El-Lakkany, Naglaa M.
  • Seif el-Din, Sayed H.
  • García-Rubia, Alfonso
  • Sebastián-Pérez, Víctor
  • Blaazer, Antoni R.
  • Heuvel, Erik de
  • Sijm, Maarten
  • Zheng, Yang
  • Salado, Irene G.
  • Munday, Jane C.
  • Maes, Louis
  • Esch, Iwan J. P. de
  • Sterk, Geert Jan
  • Augustyns, Koen
  • Leurs, Rob
  • Gil, Carmen
  • Koning, Harry de
9 p.-5 fig.-2 tab., We report the evaluation of 265 compounds from a PDE-focused library for their antischistosomal activity, assessed in vitro using Schistosoma mansoni. Of the tested compounds, 171 (64%) displayed selective in vitro activity, with 16 causing worm hypermotility/spastic contractions and 41 inducing various degrees of worm killing at 100 μM, with the surviving worms displaying sluggish movement, worm unpairing and complete absence of eggs. The compounds that did not affect worm viability (n=72) induced a complete cessation of ovipositing. 82% of the compounds had an impact on male worms whereas female worms were barely affected. In vivo evaluation in S. mansoni-infected mice with the in vitro ‘hit’ NPD-0274 at 20 mg/kg/day orally for 5 days resulted in worm burden reductions of 29% and intestinal tissue egg load reduction of 35% at 10 days posttreatment.Combination of praziquantel (PZQ) at 10 mg/kg/day for 5 days with NPD-0274 or NPD-0298 resulted in significantly higher worm killing than PZQ alone, as well as a reduction in intestinal tissue egg load, disappearance of immature eggs and an increase in the number of dead eggs., This work is part of the PDE4NPD consortium supported by Framework Program 7 of the European Commission No: 602666.Funding from RICET/FEDER funds (RD16/0027/0010), and the Ministry of Education, Culture and Sport (MECD) of Spain (Grant FPU15/1465 to V. S.-P.) is also acknowledged. Y. Z. was supported by a grant of the Chinese Science Council; A. R. B. and I. J. P. dE. were supported by the Netherlands Science Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Imidazole derivatives as promising agents for the treatment of chagas disease

  • Siciliano de Araujo, Julianna
  • García-Rubia, Alfonso
  • Sebastián-Pérez, Víctor
  • Kalejaiye, Titilola
  • da Silva, P. B.
  • Fonseca-Berzal, Cristina
  • Maes, Louis
  • Koning, Harry de
  • de Nazaré Correia Soeiro, Maria
  • Gil, Carmen
25 p.-4 fig.-2 tab., More than 100 years after being first described, Chagas disease remains endemic in 21 Latin American countries and has spread to other continents. Indeed, this disease, which is caused by the protozoan parasite Trypanosoma cruzi, is no longer just a problem for the American continents but has become a global health threat. Current therapies, i.e., nifurtimox and benznidazole (Bz), are far from being adequate, due to their undesirable effects and their lack of efficacy in the chronic phases of the disease. In this work, we present an in-depth phenotypic evaluation in T. cruzi of a new class of imidazole compounds, which were discovered in a previous phenotypic screen against different trypanosomatids and were designed as potential inhibitors of cAMP phosphodiesterases (PDEs). The confirmation of several activities similar or superior to that of Bz prompted a synthesis program of hit optimization and extended structure-activity relationship aimed at improving drug-like properties such as aqueous solubility, which resulted in additional hits with 50% inhibitory concentration (IC50) values similar to that of Bz. The cellular effects of one representative hit, compound 9, on bloodstream trypomastigotes were further investigated. Transmission electron microscopy revealed cellular changes, after just 2 h of incubation with the IC50 concentration, that were consistent with induced autophagy and osmotic stress, mechanisms previously linked to cAMP signaling. Compound 9 induced highly significant increases in both cellular and medium cAMP levels, confirming that inhibition of T. cruzi PDE(s) is part of its mechanism of action. The potent and selective activity of this imidazole-based PDE inhibitor class against T. cruzi constitutes a successful repurposing of research into inhibitors of mammalian PDEs., Funding from the EC 7th Framework Program (PDE4NPD, grant 602666), Red de Investigación Cooperativa en Enfermedades Tropicales (grant RD16/0027/0010), Fondo Europeo de Desarrollo Regional (FEDER), and Ministerio de Educación, Cultura y Deportes (grant FPU15/1465 to V.S.-P.) is acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Discovery of novel Schistosoma mansoni PDE4A inhibitors as potential agents against schistosomiasis, RUNNING TITLE: PDEs: potential targets for schistosomiasis

  • Sebastián-Pérez, Víctor
  • Schroeder, Susanne
  • Munday, Jane C.
  • Meer, Tiffany van der
  • Zaldívar-Díez, Josefa
  • Siderius, Marco
  • Koning, Harry de
  • Martínez Gil, Ana
  • Campillo, Nuria E.
  • Leurs, Rob
  • Gil, Carmen
49 p.-1 graph. abst.-8 fig.-1 tab.-4 fig. supl.-3 tab. supl., Aim: Due to the urgent need for effective drugs to treat schistosomiasis that act through a known molecular mechanism of action, we focused on a target-based approach with the aim to discover inhibitors of a cyclic nucleotide phosphodiesterase from Schistosoma mansoni (SmPDE4A)., Materials & methods: To discover new inhibitors of SmPDE4A homology models of the enzyme structure were constructed based on known human and protozoan homologs. The best two models were selected for subsequent virtual screening of our in-house chemical library., Results & conclusion: A total of 25 library compounds were selected for experimental confirmation as SmPDE4A inhibitors and after dose-response experiments, three top hits were identified. The results presented validate the virtual screening approach to identify new inhibitors for clinically relevant phosphodiesterases., EC 7 th Framework Programme (FP7-HEALTH-2013-INNOVATION-1, PDE4NPD no. 602666), RICET (RD16/0027/0010),FEDER funds and MECD (Grant FPU15/1465 to V. S.-P. and FPU13/00362 to J. Z.-D.)is acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Deciphering the enzymatic target of a new family of antischistosomal agents bearing a quinazoline scaffold using complementary computational tools

  • Sebastián-Pérez, Víctor
  • García-Rubia, Alfonso
  • Seif el-Din, Sayed H.
  • Sabra, Abdel-Nasser A.
  • El-Lakkany, Naglaa M.
  • William, Samia
  • Blundell, Tom L.
  • Maes, Louis
  • Martínez Gil, Ana
  • Campillo, Nuria E.
  • Botros, Sanaa S.
  • Gil, Carmen
13 p.-7 fig.-5 tab.-1 graph. abst., A previous phenotypic screening campaign led to the identification of a quinazoline derivative with promising in vitro activity against Schistosoma mansoni. Follow-up studies of the antischistosomal potential of this candidate are presented here. The in vivo studies in a S. mansoni mouse model show a significant reduction of total worms and a complete disappearance of immature eggs when administered concomitantly with praziquantel in comparison with the administration of praziquantel alone. This fact is of utmost importance because eggs are responsible for the pathology and transmission of the disease. Subsequently, the chemical optimisation of the structure in order to improve the metabolic stability of the parent compound was carried out leading to derivatives with improved drug-like properties. Additionally, the putative target of this new class of antischistosomal compounds was envisaged by using computational tools and the binding mode to the target enzyme, aldose reductase, was proposed., This study received funding from the EC 7th Framework Programme (FP7-HEALTH-2013-INNOVATION-1, PDE4NPD no.602666), RICET (RD16/0027/0010), FEDER funds and MECD [Grant FPU15/1465 to V. S.-P.]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

To Target or Not to Target Schistosoma mansoni Cyclic Nucleotide Phosphodiesterase 4A?

  • Zheng, Yang
  • Schroeder, Susanne
  • Kanev, Georgi K.
  • Botros, Sanaa S.
  • William, Samia
  • Sabra, Abdel-Nasser A.
  • Maes, Louis
  • Caljon, Guy
  • Gil, Carmen
  • Martínez Gil, Ana
  • Salado, Irene G.
  • Augustyns, Koen
  • Edink, Ewald
  • Sijm, Maarten
  • Heuvel, Erik de
  • Esch, Iwan J. P. de
  • Meer, Tiffany van der
  • Siderius, Marco
  • Sterk, Geert Jan
  • Brown, David
  • Leurs, Rob
Schistosomiasis is a neglected tropical disease with high morbidity. Recently, the Schistosoma mansoni phosphodiesterase SmPDE4A was suggested as a putative new drug target. To support SmPDE4A targeted drug discovery, we cloned, isolated, and biochemically characterized the full-length and catalytic domains of SmPDE4A. The enzymatically active catalytic domain was crystallized in the apo-form (PDB code: 6FG5) and in the cAMP- and AMP-bound states (PDB code: 6EZU). The SmPDE4A catalytic domain resembles human PDE4 more than parasite PDEs because it lacks the parasite PDE-specific P-pocket. Purified SmPDE4A proteins (full-length and catalytic domain) were used to profile an in-house library of PDE inhibitors (PDE4NPD toolbox). This screening identified tetrahydrophthalazinones and benzamides as potential hits. The PDE inhibitor NPD-0001 was the most active tetrahydrophthalazinone, whereas the approved human PDE4 inhibitors roflumilast and piclamilast were the most potent benzamides. As a follow-up, 83 benzamide analogs were prepared, but the inhibitory potency of the initial hits was not improved. Finally, NPD-0001 and roflumilast were evaluated in an in vitro anti-S. mansoni assay. Unfortunately, both SmPDE4A inhibitors were not effective in worm killing and only weakly affected the egg-laying at high micromolar concentrations. Consequently, the results with these SmPDE4A inhibitors strongly suggest that SmPDE4A is not a suitable target for anti-schistosomiasis therapy., This work was supported by the European Commission 7th Framework Program FP7-HEALTH-2013-INNOVATION-1 under project reference 602666 “Parasite-specific cyclic nucleotide phosphodiesterase inhibitors to target Neglected Parasitic Diseases” (PDE4NPD). Y.Z. acknowledges the China Scholarship Council (CSC) for funding (Grant No. 201506220185). LMPH is a partner of the Excellence Centre ‘Infla-Med’ (www.uantwerpen.be/infla-med (accessed on 31 March 2023)) and participates in COST Action CA21111., Peer reviewed